SXTC (China SXT Pharmaceuticals) EBIT per Share: $-7.85 (TTM As of Mar. 2026)


SXTC China SXT Pharmaceuticals Inc SXTC
27 GF Score
Price $2.45
GF Value $2.05
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals EBIT per Share?

China SXT Pharmaceuticals SXTC -0.41% 27 EBIT per Share is $-7.85 as of Mar. 2026. GuruFocus rates SXTC with a GF Score™ of 27/100 and a GF Value™ of $2.05 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 809 Drug Manufacturers companies, China SXT Pharmaceuticals ranks worse than 123609.27% on this metric.

China SXT Pharmaceuticals's EBIT per Share for the six months ended in Mar. 2026 was $0.33. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.85.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for China SXT Pharmaceuticals's EBIT per Share or its related term are showing as below:

SXTC's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

China SXT Pharmaceuticals's EBIT for the six months ended in Mar. 2026 was $0.20 Mil.

China SXT Pharmaceuticals  (NAS:SXTC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

China SXT Pharmaceuticals EBIT per Share Related Terms

China SXT Pharmaceuticals EBIT per Share Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals EBIT per Share Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1,277.00 -295.00 -9.03

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,402.50 -206.67 -22.12 -8.19 0.33
SXTC
27GF Score
China SXT Pharmaceuticals Inc SXTC
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China SXT Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

China SXT Pharmaceuticals's EBIT per Share for the fiscal year that ended in Mar. 2026 is calculated as

EBIT per Share(A: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-6.142/0.680
=-9.03

China SXT Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=0.195/0.586
=0.33

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-7.85 mean?
China SXT Pharmaceuticals (SXTC) has a EBIT per Share of $-7.85 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on China SXT Pharmaceuticals and its competitors. According to the industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is China SXT Pharmaceuticals' EBIT per Share too high?
China SXT Pharmaceuticals' current EBIT per Share is $-7.85. Based on the distribution chart, China SXT Pharmaceuticals ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' EBIT per Share compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 809 companies for EBIT per Share. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current EBIT per Share is $-7.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (SXTC) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $2.45 — trading 19.5% above its estimated fair value. The current EBIT per Share is $-7.85. China SXT Pharmaceuticals' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current EBIT per Share is $-7.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (SXTC) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be overvalued. The current stock price of $2.45 is trading 19.5% above its estimated GF Value™ of $2.05. GuruFocus considers China SXT Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for SXTC:

  • EBIT per Share: $-7.85
  • GF Value™: $2.05 vs. price of $2.45 (19.5% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the SXTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
27GF Score

Get the complete analysis for SXTC

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.45
Price
$2.05
GF Value